RG 6498
Alternative Names: RG6498Latest Information Update: 06 Feb 2026
At a glance
- Originator Roche
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 29 Jan 2026 Phase-I clinical trials in Inflammatory bowel diseases in USA (unspecified route) (Roche pipeline, January 2026)